Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studies

被引：0
|
作者：
Sharon Walmsley
Don E. Smith
Miguel Górgolas
Pedro E. Cahn
Thomas Lutz
Karine Lacombe
Princy N. Kumar
Brian Wynne
Richard Grove
Gilda Bontempo
Riya Moodley
Chinyere Okoli
Michelle Kisare
Bryn Jones
Andrew Clark
Mounir Ait-Khaled
机构：
[1] University Health Network,
[2] Albion Centre,undefined
[3] Fundación Jiménez Díaz,undefined
[4] Universidad Autónoma de Madrid,undefined
[5] Fundación Huésped,undefined
[6] Infektiologikum,undefined
[7] Hôpital Saint-Antoine,undefined
[8] Georgetown University Medical Center,undefined
[9] ViiV Healthcare,undefined
[10] GSK,undefined
[11] ViiV Healthcare,undefined
[12] ViiV Healthcare,undefined
来源：
AIDS Research and Therapy | / 21卷
关键词：
Aging; Comorbidity; DTG/3TC; HIV-1; Polypharmacy; Single-tablet regimen; Suppressed switch;  ≥ 50 years;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Switching efavirenz to rilpivirine in virologically suppressed adolescents with HIV: a multi-centre 48-week efficacy and safety study in Thailand
    Phongsamart, Wanatpreeya
    Jantarabenjakul, Watsamon
    Chantaratin, Sasitorn
    Anugulruengkitt, Suvaporn
    Suntarattiwong, Piyarat
    Sirikutt, Pakpen
    Kosalaraksa, Pope
    Maleesatharn, Alan
    Chokephaibulkit, Kulkanya
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 (01)
  • [22] Effectiveness, safety and tolerability of dolutegravir/lamivudine versus tenofovir alafenamide/emtricitabine/bictegravir in a real-life cohort of HIV-1 virologically suppressed treatment experienced people living with HIV
    Tordi, S.
    De Socio, G. V.
    Altobelli, D.
    Gidari, A.
    Zoffoli, A.
    Francisci, D.
    HIV MEDICINE, 2023, 24 : 153 - 155
  • [23] Safety and effectiveness of switching to Abacavir/Lamivudine plus rilpivirine for maintenance therapy in virologically suppressed HIV-1 individuals in Singapore (SEALS)
    Lim, Z. C.
    Hoo, G. S.
    Ang, J. H.
    Teng, C. B.
    Ang, L. W.
    Lee, C. C.
    Leo, Y. S.
    Law, H. L.
    Ng, O. T.
    Wong, C. S.
    AIDS RESEARCH AND THERAPY, 2021, 18 (01)
  • [24] Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting
    Lombardi, Francesca
    Belmonti, Simone
    Moschese, Davide
    Fabbiani, Massimiliano
    Borghetti, Alberto
    Ciccullo, Arturo
    Visconti, Elena
    Di Giambenedetto, Simona
    HIV RESEARCH & CLINICAL PRACTICE, 2022, 23 (01) : 28 - 36
  • [25] Safety and effectiveness of switching to Abacavir/Lamivudine plus rilpivirine for maintenance therapy in virologically suppressed HIV-1 individuals in Singapore (SEALS)
    Z. C. Lim
    G. S. Hoo
    J. H. Ang
    C. B. Teng
    L. W. Ang
    C. C. Lee
    Y. S. Leo
    H. L. Law
    O. T. Ng
    C. S. Wong
    AIDS Research and Therapy, 18
  • [26] Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naive, virologically-suppressed patients: Latest evidence from the literature on their efficacy and safety
    Cento, Valeria
    Perno, Carlo Federico
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2020, 20 : 228 - 237
  • [27] Impact of HBV serological status on HIV virological efficacy of two-drug antiretroviral regimens: A retrospective observational study on virologically suppressed people with HIV switching to lamivudine/dolutegravir
    Salvo, Pierluigi Francesco
    Ciccullo, Arturo
    Visconti, Elena
    Lombardi, Francesca
    Torti, Carlo
    Di Giambenedetto, Simona
    Baldin, Gianmaria
    HIV MEDICINE, 2025, 26 (04) : 650 - 653
  • [28] Quantitation of cellular HIV-1 DNA levels by droplet digital PCR in virologically-suppressed patients switching to dolutegravir plus lamivudine: a prospective study
    Lombardi, F.
    Belmonti, S.
    Borghetti, A.
    Ciccullo, A.
    Baldin, G.
    Emiliozzi, A.
    Moschese, D.
    Cauda, R.
    Di Giambenedetto, S.
    HIV MEDICINE, 2019, 20 : 77 - 77
  • [29] Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial
    Maggiolo, Franco
    Rizzardini, Giuliano
    Molina, Jean-Michel
    Pulido, Federico
    De Wit, Stephane
    Vandekerckhove, Linos
    Berenguer, Juan
    D'Antoni, Michelle L.
    Blair, Christiana
    Chuck, Susan K.
    Piontkowsky, David
    Martin, Hal
    Haubrich, Richard
    McNicholl, Ian R.
    Gallant, Joel
    INFECTIOUS DISEASES AND THERAPY, 2021, 10 (02) : 775 - 788
  • [30] Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial
    Franco Maggiolo
    Giuliano Rizzardini
    Jean-Michel Molina
    Federico Pulido
    Stephane De Wit
    Linos Vandekerckhove
    Juan Berenguer
    Michelle L. D’Antoni
    Christiana Blair
    Susan K. Chuck
    David Piontkowsky
    Hal Martin
    Richard Haubrich
    Ian R. McNicholl
    Joel Gallant
    Infectious Diseases and Therapy, 2021, 10 : 775 - 788
12345